| 000 | 01883 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250518060928.0 | ||
| 264 | 0 | _c20200813 | |
| 008 | 202008s 0 0 eng d | ||
| 022 | _a2051-1426 | ||
| 024 | 7 |
_a10.1186/s40425-019-0725-7 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aShi, Jing | |
| 245 | 0 | 0 |
_aCarboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy. _h[electronic resource] |
| 260 |
_bJournal for immunotherapy of cancer _c09 2019 |
||
| 300 |
_a246 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
| 650 | 0 | 4 | _aApoptosis |
| 650 | 0 | 4 |
_aCD8-Positive T-Lymphocytes _xdrug effects |
| 650 | 0 | 4 | _aCell Proliferation |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 |
_aFlavones _xpharmacology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunotherapy |
| 650 | 0 | 4 |
_aIndoleamine-Pyrrole 2,3,-Dioxygenase _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aKynurenine _xmetabolism |
| 650 | 0 | 4 |
_aLymphocyte Activation _ximmunology |
| 650 | 0 | 4 |
_aMelanoma _xdrug therapy |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, Inbred BALB C |
| 650 | 0 | 4 | _aMice, Inbred C57BL |
| 650 | 0 | 4 | _aMice, Transgenic |
| 650 | 0 | 4 |
_aReceptors, Aryl Hydrocarbon _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aTriazoles _xpharmacology |
| 650 | 0 | 4 |
_aTryptophan _xpharmacology |
| 650 | 0 | 4 | _aTumor Cells, Cultured |
| 650 | 0 | 4 |
_aTumor Microenvironment _xdrug effects |
| 700 | 1 | _aChen, Chen | |
| 700 | 1 | _aJu, Rui | |
| 700 | 1 | _aWang, Qingzhu | |
| 700 | 1 | _aLi, Juan | |
| 700 | 1 | _aGuo, Lei | |
| 700 | 1 | _aYe, Caiying | |
| 700 | 1 | _aZhang, Dechang | |
| 773 | 0 |
_tJournal for immunotherapy of cancer _gvol. 7 _gno. 1 _gp. 246 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1186/s40425-019-0725-7 _zAvailable from publisher's website |
| 999 |
_c30102216 _d30102216 |
||